BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buonaguro L, Tagliamonte M, Petrizzo A, Damiano E, Tornesello ML, Buonaguro FM. Cellular prognostic markers in hepatocellular carcinoma. Future Oncol 2015;11:1591-8. [PMID: 26043213 DOI: 10.2217/fon.15.39] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Li Y, Li S, Duan X, Yang C, Xu M, Chen L. Macrophage Phenotypes and Hepatitis B Virus Infection. J Clin Transl Hepatol. 2020;8:424-431. [PMID: 33447526 DOI: 10.14218/jcth.2020.00046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
2 Tagliamonte M, Petrizzo A, Tornesello ML, Ciliberto G, Buonaguro FM, Buonaguro L. Combinatorial immunotherapy strategies for hepatocellular carcinoma. Curr Opin Immunol 2016;39:103-13. [PMID: 26851637 DOI: 10.1016/j.coi.2016.01.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
3 An Y, Wang Q, Zhang G, Sun F, Zhang L, Li H, Li Y, Peng Y, Zhu W, Ji S, Guo X. OSlihc: An Online Prognostic Biomarker Analysis Tool for Hepatocellular Carcinoma. Front Pharmacol 2020;11:875. [PMID: 32587519 DOI: 10.3389/fphar.2020.00875] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Wang TC, An TZ, Li JX, Pang PF. Systemic Inflammation Response Index is a Prognostic Risk Factor in Patients with Hepatocellular Carcinoma Undergoing TACE. Risk Manag Healthc Policy 2021;14:2589-600. [PMID: 34188570 DOI: 10.2147/RMHP.S316740] [Reference Citation Analysis]
5 Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Tagliamonte M, Buonaguro L. Cellular prognostic markers in hepatitis-related hepatocellular carcinoma. Infect Agent Cancer 2018;13:10. [PMID: 29599818 DOI: 10.1186/s13027-018-0183-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
6 Schobert IT, Savic LJ, Chapiro J, Bousabarah K, Chen E, Laage-Gaupp F, Tefera J, Nezami N, Lin M, Pollak J, Schlachter T. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. Eur Radiol 2020;30:5663-73. [PMID: 32424595 DOI: 10.1007/s00330-020-06931-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
7 Petrizzo A, Buonaguro L. Application of the Immunoscore as prognostic tool for hepatocellular carcinoma. J Immunother Cancer. 2016;4:71. [PMID: 27879973 DOI: 10.1186/s40425-016-0182-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
8 Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget. 2016;7:25087-25102. [PMID: 26943571 DOI: 10.18632/oncotarget.7837] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
9 Fan Y, Qian X, Zhang C. U/G SNP rs111904020 in 3′UTR of STAT3 regulated by miR-214 promotes hepatocellular carcinoma development in Chinese population. Tumor Biol 2016;37:14629-35. [DOI: 10.1007/s13277-016-5352-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
10 Buonaguro FM, Tornesello ML, Buonaguro L. Foreword. Cancer biomarkers. Future Oncol 2015;11:1585-6. [PMID: 26043211 DOI: 10.2217/fon.15.74] [Reference Citation Analysis]
11 Zhang Q, Xiao Z, Sun S, Wang K, Qian J, Cui Z, Tao T, Zhou J. Integrated Proteomics and Bioinformatics to Identify Potential Prognostic Biomarkers in Hepatocellular Carcinoma. Cancer Manag Res 2021;13:2307-17. [PMID: 33732023 DOI: 10.2147/CMAR.S291811] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]